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ORIGINAL ARTICLE
See Editorial by Heijman and Dobrev
BACKGROUND: Evidence has emerged that small-conductance Ca2+-
activated K+ (SK) channels constitute a new target for treatment of atrial 
fibrillation (AF). SK channels are predominantly expressed in the atria as 
compared with the ventricles. Various marketed antiarrhythmic drugs are 
limited by ventricular adverse effects and efficacy loss as AF progresses.
METHODS AND RESULTS: A total of 43 pigs were used for the studies. 
AF reversion in conscious long-term tachypaced pigs: Pigs were subjected 
to atrial tachypacing (7 Hz) until they developed sustained AF that 
could not be reverted by vernakalant 4 mg/kg (18.8±3.3 days of atrial 
tachypacing). When the SK channel inhibitor AP14145 was tested in 
these animals, vernakalant-resistant AF was reverted to sinus rhythm, 
and reinduction of AF by burst pacing (50 Hz) was prevented in 8 of 8 
pigs. Effects on refractory period and AF duration in open chest pigs: The 
effects of AP14145 and vernakalant on the effective refractory periods 
and acute burst pacing-induced AF were examined in anaesthetized open 
chest pigs. Both vernakalant and AP14145 significantly prolonged atrial 
refractoriness and reduced AF duration without affecting the ventricular 
refractoriness or blood pressure in pigs subjected to 7 days atrial 
tachypacing, as well as in sham-operated control pigs.
CONCLUSIONS: SK currents play a role in porcine atrial repolarization, 
and pharmacological inhibition of these with AP14145 demonstrates 
antiarrhythmic effects in a vernakalant-resistant porcine model of AF. 
These results suggest SK channel blockers as potentially interesting anti-
AF drugs.
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Effective, safe, and tolerable pharmacological treat-ment for atrial fibrillation (AF) remains an unmet need. The latest medication to reach the market 
for intravenous cardioversion was the combined sodi-
um and potassium channel inhibitor vernakalant, how-
ever not yet available in the United States. Vernakalant 
terminated ≈50% of episodes of AF lasting <7 days in 
randomized controlled studies, with its highest conver-
sion rate during the first few days while after 8 to 45 
days of AF, the conversion rate was <10%, which was 
not statistically different from that of placebo.1,2
If lasting for >24 hours, AF promotes further pro-
gression of the disease—a phenomenon described as 
AF begets AF.3 If atrial remodeling continues, AF often 
progresses to more sustained forms and becomes more 
resistant to both pharmacological and nonpharmaco-
logical treatments, including ablation.4–6 Among con-
tributing factors, an increased influx of calcium seems 
to promote fibrosis development and remodeling.7
Three subtypes of small-conductance calcium-
activated K+ channels, SK1, SK2, and SK3, are repre-
sented in the heart. They are all exclusively activated by 
intracellular Ca2+, and the current conducted by these 
channels is recognized as IKCa. Originally, SK channels 
were cloned from the central nervous system where they 
contribute to the afterhyperpolarization of the neuronal 
action potential.8 With the finding of SK channels in car-
diac tissue, it was demonstrated that these channels are 
WHAT IS KNOWN?
• Small-conductance Ca2+-activated K+ (SK) channels 
are predominantly expressed in the atria as com-
pared with the ventricles.
• Various marketed antiarrhythmic drugs are limited 
by ventricular adverse effects and efficacy loss as 
atrial fibrillation progresses.
WHAT THE STUDY ADDS?
• Data from a newly developed porcine model of 
vernakalant‐resistant atrial fibrillation showing 
that SK channel currents play a role in porcine 
atrial repolarization.
• Data showing that pharmacological inhibition of 
SK channel current with AP14145 demonstrates 
antiarrhythmic effects in a vernakalant‐resistant 
porcine model of atrial fibrillation.
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also important for the repolarization of cardiac action 
potentials.8–11 Confirmation of the role of SK channels in 
human AF has since been provided in several genome-
wide association studies concluding that common vari-
ants in the genes encoding SK2 and SK3 are associated 
with AF.12–14 We demonstrated that IKCa inhibition can 
terminate AF or protect against its induction in models 
of AF in isolated perfused heart preparations from rat, 
guinea pig, and rabbit, as well as in in vivo models of 
AF in rat, dog, and horse.8–11,15 We also obtained evi-
dence that SK channels play a functional role in right 
atrial (RA) appendage tissue, but not ventricular tissue, 
from patients in sinus rhythm (SR), as well as patients 
with >6 months of AF, and that inhibition of IKCa with 
the SK channel inhibitor NS8593 prolonged refractory 
periods in atrial tissue from these patients.16 Preliminary 
evidence suggests that the IKCa is increased in patients 
with paroxysmal AF compared with patients in SR, and 
IKCa inhibition by the peptide apamin was associated 
with a 4-fold increased action potential prolongation in 
cells from patients in paroxysmal AF.17
Significant antiarrhythmic effects in normal and 
remodeled atria, without adverse effects in the ventricles, 
have long been a desirable, but nonachievable, therapeu-
tic goal. This seems possible by inhibition of the SK chan-
nels, which may, therefore, qualify as a promising target 
for the development of a novel agent for treatment of AF. 
In a preclinical canine model of vagotonic AF, vernaka-
lant cardioverted 7 of 7 dogs at a dose of 4 mg/kg.18
To obtain a preclinical model better simulating clini-
cal AF, we performed long-lasting atrial tachypacing 
(AT) in pigs to develop sustained AF until it was no lon-
ger possible to convert with a clinically relevant dose 
of vernakalant. In this model of sustained vernakalant-
resistant AF, we tested whether an SK channel inhibi-
tor, the tool compound AP14145, could successfully 
convert AF to SR and protect against reinduction of AF.
METHODS
In Vitro Electrophysiology
Effects of AP14145 on hSK3 (KCa2.3) and hERG (hKV11.1) 
were investigated by automated patch clamp (Qpatch; Biolin 
Scientific, Sophion, Denmark) as previously described.19 
Likewise, the effect on rNaV1.5 was evaluated as earlier 
described20 but with a modified voltage protocol so that 
rNaV1.5 currents were elicited with 1-second interval by a 
50-ms depolarizing step to −20 mV from a holding poten-
tial of −120 mV (a total of 80 pulses). Effect of AP14145 
on L-type calcium channels was investigated by automated 
patch clamping (Qpatch; Biolin Scientific) using a hCaV 1.2 
stable cell line (α1C, β2C, and α2delta; SB Drug Discovery, 
Glasgow, United Kingdom).
Off-target effects on Kir3.1/Kir3.4 (IKACh), KV1.5 (IKur), 
KV7.1/KCNE1 (IKs), KV4.3/KChiP2 (Ito), and Kir2.1 (IK1) were 
investigated using 2-electrode voltage-clamp experiments on 
Xenopus laevis oocytes expressing the relevant channels.19 For 
further details, please see Data Supplement.
Animal Models
All animal studies were performed under a license from 
the Danish Ministry of Environment and Food (license 
No. 2012-15-2934-00083) and in accordance with the 
Danish guidelines for animal experiments according to the 
European Commission Directive 86/609/EEC. A total of 43 
Danish landrace pigs (from Krigsagergård w. Henrik Larsen, 
Gilleleje, Denmark; 12–13 weeks old, 30–35 kg gilts) were 
studied. The pigs were divided into 4 main groups: (1) open 
chest surgery (n=21), (2) cardioversion in conscious pigs 
(n=8), (3) expression studies (n=12), and (4) pharmacoki-
netic studies (n=2). The open chest surgery group consisted 
of pigs subjected to 1-week AT and sham-operated time 
matched controls (CTRL). The group for conscious cardio-
version studies consisted of long-term AT pigs with persis-
tent AF that could not be converted by a clinically relevant 
dose of vernakalant. The group for expression studies was 
divided into long-term AT pigs and control pigs.
All pigs underwent the following procedure: After 
pre-medication with zoletil pig mixture (250 mg dry 
tiletamin+zolazepam, 6.5 mL xylazine 20 mg/mL, 1.25 ket-
amine 100 mg/mL, 2.5 mL butorphanol 10 mg/mL, and 2 
mL methadone 10 mg/mL) 0.1 mL/kg given intramuscularly, 
the pig was given an intravenous infusion of propofol and 
fentanyl (15 mg/kg per hour and 50 µg/kg per hour, respec-
tively) and intubated and ventilated with a tidal volume of 
10 mL/kg and a respiration frequency of 12 to 14 per min-
utes. During surgery arterial partial pressure of carbon diox-
ide (Paco2), blood pressure and ECG were monitored, and 
the pig was given 6 mL/kg per hour isotonic saline solution. 
Under aseptic conditions and fluoroscopic guidance, a bipo-
lar pacing-electrode was inserted into the RA appendage and 
connected to a neurostimulator (Medtronic Synergy versitrel 
or Itrel 3) implanted subcutaneously in the neck region. The 
pigs in the long-term AT group received a central venous 
catheter in the internal jugular vein with an exit in the dorsal 
neck region.
Open Chest Surgery
In the 1-week AT pigs, after 7 days recovery after pace-
maker implantation, the pacemakers were turned on and 
the RA was paced 420 beats per minute (BPM) for 7 days. 
To avoid symptoms of heart failure caused by a high ventric-
ular rate because of pacing, the pigs were medicated with 
digoxin (250 µg/d) starting 4 days before turning on the 
pacemaker and discontinued 2 days before open chest sur-
gery. The same procedure was used in the CTRL pigs except 
that the pacemakers remained turned off in this group. 
Sixteen hours before study days, the pacemaker was deac-
tivated. On study days, pigs were anesthetized as described 
for the pacemaker implantation. After median sternotomy, 
custom-made hook-shaped teflon-coated stainless steel 
electrodes for recording and stimulation were inserted into 
the left atrial (LA) appendage and the left ventricle (LV). 
If the placement of the electrodes gave rise to AF, which 
was the case in all of the 1-week AT pigs, the AF was DC 
cardioverted (Zoll M Series, ZOLL Medical, Cheshire, United 
Kingdom) with the electrodes placed on the LA and RA 
using 5 to 30 J as appropriate. After conversion to SR, the 
heart was allowed 30 minutes of stabilization.
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A programmable stimulator (Hugo Sachs, Germany) was 
used to deliver 2-ms double-rheobase current pulses, and the 
LA effective refractory period (ERP), the LV ERP, and the mean 
AF duration after burst pacing were measured. The LV ERP 
and LA ERP were measured at a basic cycle length of 400 
ms. The ERP was determined as the longest S1-S2 failing to 
capture, with 10 basic stimuli (S1) followed by a premature 
extra stimulus (S2) with 5 ms increments. AF was induced by 
burst pacing at 50 Hz and 10 V. The mean AF duration was 
based on 10 AF inductions in each pig or 5 AF inductions if 
the mean AF duration of the first 5 AF durations was >1 min-
ute and <5 minutes or as many AF inductions as time allowed 
(usually 1 or 2) within 30 minutes if the AF durations lasted 
>5 minutes. In 12 of 14 1-week AT pigs AF was induced by 
the first S2 stimulus after the LA ERP and was sustained for 
at least 30 minutes after which drug treatment was started.
Before the experiments, each pig was randomly assigned 
to receive either AP14145 or vernakalant 30 minutes after 
induction of the first AF episode.
Vernakalant was given as an infusion of 0.12 mg/kg per 
minute (60 minutes) followed by a maintenance infusion of 
0.08 mg/kg per minute to produce a steady plasma concen-
tration of ≈4000 ng/mL as described in ref 21, equivalent to the 
maximal plasma concentration measured in patients in the 
ACT I clinical trial (Arrhythmia Conversion Trial).22 Recordings 
after baseline in the groups receiving vernakalant were all 
conducted at steady state plasma concentration of vernaka-
lant. AP14145 was given as 3 consecutive bolus injections for 
1 to 2 minutes of 5, 8, and 8 mg/kg with 30 minutes intervals. 
Recordings in the groups receiving AP14145 were conducted 
a few minutes after each bolus dose.
Cardioversion in Conscious Pigs
In the long-term AT pigs, after 7 days of recovery, the pace-
makers were turned on and the RA was paced at 420 BPM 
(Figure 1). The pigs were medicated with digoxin (250 µg/d) 
starting 4 days before turning on the pacemaker. After 7 
days pacing, the pigs were Holter-monitored (Televet 100; 
Engel Engineering Service GmbH, Heusenstamm, Germany) 
while the pacemaker was turned off. Sustained AF was 
defined as AF that was sustained after the pacemaker was 
turned off during >10 minutes monitoring and an additional 
10 minutes with infusion of saline (1 mL/kg) followed by 30 
minutes monitoring, a total of 50 minutes of AF. When sus-
tained AF had been confirmed, vernakalant (4 mg/kg) was 
infused for 10 minutes, and the pig was monitored for an 
additional 30 minutes. If AF converted at any point, the pig 
was paced 420 BPM for another 7 days, and the procedure 
was repeated. When AF could no longer be converted to 
SR by vernakalant, the pig was paced 420 BPM for another 
24 to 48 hours to allow vernakalant to be cleared from the 
system (half-life, 2–3 hours). After this, the pacemaker was 
turned off under Holter-monitoring. After having observed 
10 minutes of AF, 1 mL/kg vehicle was injected over 2 min-
utes, and the ECG was monitored for 30 minutes. When AF 
did not convert to SR within this period, 5 mg/kg AP14145 
was injected over 2 minutes, and the ECG was monitored 
for 30 minutes. If AF converted within 30 minutes, burst 
pacing with 50 Hz was given thrice. If AF did not convert 
or if a single AF episode lasting for >10 minutes could be 
induced with burst pacing, an additional 8 mg/kg AP14145 
was injected over 2 minutes and the ECG was monitored 
for 30 minutes. If AF converted within 30 minutes, burst 
pacing with 50 Hz for 5 to 15 seconds was given thrice. 
If AF did not convert or an AF episode of at least 10 min-
utes duration could be induced with burst pacing, a final 
dose of 8 mg/kg AP14145 was injected over 2 minutes and 
the ECG was monitored for another 30 minutes. If at any 
point AP14145 injection gave rise to unexpected adverse 
effects, the pig was sedated by a small dose of zoletil while 
the experiment was completed. If at any point AF was con-
verted and could not be reinduced with burst pacing, the 
experiment was terminated. Cardioversion was considered 
successful if AF was converted. Protection against reinduc-
tion of AF was considered successful if AF lasting >10 min-
utes could not be reinduced by burst pacing.
Pharmacokinetic Measurements
Two pigs underwent pharmacokinetic studies and were 
pre-medicated, anaesthetized, intubated, and ventilated as 
described above. Paco2, temperature, and ECG were moni-
tored. Invasive blood pressure was measured in the right 
femoral artery, and the pig was given 6 mL/kg per hour iso-
tonic salt solution in an ear vein. At T=0, 5 mg/kg AP14145 
was infused in the left external jugular vein, and blood sam-
ples were taken from the right femoral vein at (in minutes) 
T=−10, 5, 10, 15, 20, 30, 40, 60, 80, 100, 140, and 180 
and stored in heparin treated tubes. Blood samples were 
centrifuged at 2G for 5 minutes at 4°C, and the plasma 
samples analyzed for AP14145 concentration at CiToxLAB 
ScanTox AS, Ejby, Denmark.
KCNNx Expression in Pig Hearts
Cardiac tissue from each of the 4 heart chambers was 
obtained from long-term AT pigs (n=6) or healthy controls 
(HC; n=6). After pre-medication with zoletil pig mixture 
(250 mg dry tiletamin+zolazepam, 6.5 mL xylazine 20 mg/
mL, 1.25 ketamine 100 mg/mL, 2.5 mL butorphanol 10 
mg/mL, and 2 mL methadone 10 mg/mL) 0.1 mL/ kg given 
intramuscularly, the pigs were euthanized by intravenous 
injection of pentobarbital 200 mg/mL, and the hearts were 
excised and placed in ice-cold cardioplegic solution (NaCl 
110.0, KCl 16.0, MgCl2 16.0, CaCl2 1.2, and NaHCO3 
10.0 mmol/L). Total RNA from tissue samples was extracted 
according to manufacturer’s instruction (miRNeasy Mini 
Kit, Qiagen, CA). RNA was reverse transcribed to cDNA 
using the nanoscript2 kit (Primerdesign, United Kingdom). 
Expression profiling of the SK channels (KCNN1, KCNN2, 
and KCNN3) was performed using quantitative real-time 
quantitative polymerase chain reaction with Taqman dou-
ble dye probes (Primerdesign, United Kingdom). For further 
details, please see Data Supplement.
Data and Statistical Analyses
GraphPad Prism software (GraphPad Software, San 
Diego, CA) and Chart 7 software (ADinstruments) were 
used for data analyses and figures. Continuous data 
other than AF durations were summarized using the 
mean±SEM. AF durations were log-transformed to pass a 
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Kolmogorov–Smirnov normality test. In the text, AF dura-
tion was given as a back transformation the mean of log 
AF duration (10mean of AF durationlog ) followed by the interval 
(10mean of AF duration SEMlog − −10mean of AF duration SEMlog + ) in parentheses. 
In figures, the AF duration is shown as the raw AF dura-
tion on a logarithmic scale. Expression data were log-trans-
formed to obtain a more Gaussian distribution. In figures, 
the expression data are shown as the raw values on a loga-
rithmic scale.
Wilcoxon matched pairs signed-rank test was used to 
compare pooled expression data from AF and HC pigs for LA 
versus LV and RA versus right ventricle. Mann–Whitney test 
was used to compare the differences in expression of KCNN2 
and KCNN3 in AF versus HC, as well as LA ERP, LV ERP, and 
AF durations of CTRL and 1-week AT groups. Fisher exact test 
was used to compare the number of pigs with AF durations 
>30 minutes in the CTRL and 1-week AT groups. Ordinary 
1-way ANOVA and Sidak correction for multiple compari-
sons test were used to compare mean values of heart rates 
in 1-week AT before AT, right after AT, and at vernakalant-
resistant AF, as well as for comparing LA ERP, LV ERP, and log 
AF duration by concentration of AP14145 and vernakalant as 
compared with the respective baseline values. 
P values are given with 3 significant digits, and values of 
P<0.05 were considered statistically significant.
Compounds and Solution
Vernakalant (Brinavess) was purchased from a Danish phar-
macy as a 20-mg/mL solution for intravenous infusion. Before 
infusion, it was diluted in sterile isotonic saline to yield a final 
concentration of 4 mg/mL. AP14145 is an Acesion Pharma 
proprietary compound and was synthesized at Syngene 
International, Bangalore, India. AP14145 was dissolved in 
dimethyl sulfoxide for cellular electrophysiology or saline and 
30% hydroxypropylbetacyclodextrin (Roquette, France) for 
pig experiments. The solution was sterile filtered before use.
RESULTS
AP14145: a New Small Molecule SK 
Channel Inhibitor
The small molecule compound AP14145 (N-(2-{[(1R)-
1-[3-(trifluoromethyl)phenyl]ethyl]amino}-1H-1,3-ben-
zodiazol-4-yl) acetamide (Figure 2) was developed as a 
novel potent SK3 channel inhibitor and has structural 
similarities to the earlier published SK channel inhibitor 
NS8593.23
AP14145 demonstrated an IC50 in whole-cell patch 
clamp on the human SK3 channel of 1.3±0.4 µmol/L 
with a Hill-slope of 1.4±0.7 showing no cooperativity 
(Figure 3, left). To investigate the selectivity of AP14145, 
the effect of the compound was tested on a panel 
of cardiac ion channels (Figure I in the Data Supple-
ment). AP14145 inhibited hERG (KV11.1) with an IC50 
of 71.8±0.5 µmol/L and Kir3.1/Kir3.4 (IKACh) with an IC50 
of 9.3±0.4 µmol/L (Figure 3, left) and did not produce 
any significant effects on KV1.5 (IKur), KV7.1/KCNE1 (IKs), 
KV4.3/KChiP2 (Ito), and Kir2.1 (IK1) in 30 µmol/L or on 
NaV1.5 (15 µmol/L; INa; Figure  3, middle). Concentra-
tions from 1 to 10 µmol/L AP14145 produced no signif-
icant block of CaV1.2, whereas AP14145 at 30 µmol/L 
changed the baseline significantly more than dimethyl 
sulfoxide (54±3% versus 28±7%; Figure 3, right).
Figure 1. Flowchart for cardiover-
sion of vernakalant-resistant atrial 
fibrillation (AF) in conscious pigs.  
BPM indicates beats per minute.
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SK2 and SK3 Are Expressed in Pig Atria
The expression of SK channels in porcine heart has not 
been previously described. To further substantiate that 
effects of AP14145 on atrial electrophysiology were 
mediated by SK channels, we investigated the expres-
sion profile of KCNN1, KCNN2, and KCNN3 (SK1–3) in 
the hearts of pigs with sustained AF, as well as con-
trols. KCNN1 was only found in diminutive amounts in 
all chambers of both HC and AF pigs (data not shown).
KCNN2 was expressed in both atria and ventricles 
(Figure  4, left). The expression levels of KCNN2 were 
not found to be significantly affected by tachypacing 
and the presence of AF in any of the chambers. A high-
er level (≈2-fold) of KCNN2 was found in LA compared 
with LV (P=0.005) and in RA compared with right ven-
tricle (P=0.002) in HC and AF pigs.
KCNN3 was expressed in both atria and ventricles 
(Figure 4, right). The expression levels of KCNN3 were 
not found to be significantly affected by tachypacing 
and the presence of AF in any of the chambers. No sta-
tistically significant difference between LA compared 
with LV (P=0.424) or RA compared with right ventricle 
(P=0.077) was observed.
Pharmacokinetic Results
An exponential 1-phase decay model fitted the obser-
vations made with regard to plasma concentration of 
AP14145 over time with R2=0.97, Cmax=8355 nmol/L, 
t½=24.3 minutes, and τ=35 minutes (Figure 5, left). 
Using these values and the formula C C e
max
t
=
− /τ, as 
well as a plasma protein binding from minipig plasma 
of 88%, the free plasma concentrations of AP14145 
at any given time during the experiments can be cal-
culated for the dosing regimen used (Figure 5, right). 
According to these calculations, the maximal free 
plasma concentrations of AP14145 after each bolus 
injection were 1.0, 2.0, and 2.5 µmol/L (Figure  5, 
right), corresponding to 43%, 54%, and 67% IKCa-
inhibition, assuming Michaelis–Menten kinetics.
Open Chest Experiments: 1-Week AT 
and CTRL Pigs
Effects of 1-Week AT
Neither the LA ERP of 69±8 ms nor the LV ERP of 
183±12 ms in the 1-week AT pigs was significantly 
different from their CTRL counterparts of 75±8 and 
181±6 ms, respectively (P=0.517 for LA ERP and 
P=0.859 for LV ERP). However, the 1-week AT gave 
rise to significantly longer AF durations as compared 
with the CTRL with mean AF durations of 1130 sec-
onds (822–1553 seconds) and 175 seconds (93–329 
seconds), respectively (P=0.004). Significantly, more 
pigs in the 1-week AT group (10 of 12) had AF dura-
tions >30 minutes than in the CTRL group (2 of 9; 
Figure 2. Small-conductance Ca2+-
activated K+ channel inhibitors 
AP14145 (left) and NS8593 (right).
Figure 3. Effect of AP14145 on heterologous expressed ion channels.  
Left, Concentration response curves of AP14145 effects on hSK3 (n=11), hERG (n=5), and Kir3.1/Kir3.4 (n=6). Middle, % Inhibi-
tion of KV7.1/KCNE1 (n=9), Kir2.1 (n=5), KV1.5 (n=5), and KV4.3/KChiP2 (n=5) by 30 µmol/L AP14145 and on NaV1.5 by 15 µmol/L 
AP14145 (n=3). Right, % Inhibition of hCaV1.2 by dimethyl sulfoxide (n=3) or AP14145 by 10 and 30 µmol/L (n=6). hERG, 
NaV1.5, CaV1.2, and SK3 are measured by automated patch clamping and the remaining by 2-electrode voltage-clamp.
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P=0.009). Despite treatment with digoxin, 1-week AT 
increased the mean ventricular rate from 174±6 to 
258±19 BPM right after initiation of AT (P<0.003), and 
the mean ventricular rate remained elevated (221±13 
BPM; P=0.028) also after long-term AT when vernaka-
lant-resistant AF was present.
Effects of Compounds in CTRL Pigs
In the CTRL pigs, both vernakalant and the low dose 
of AP14145 failed to significantly increase the LA ERP 
(Table 1; Figure 6, top). The higher doses of AP14145 
caused a significant increase of LA ERP. The increase in 
LA ERP with AP14145 was dose dependent. Concomi-
tant with the increase in LA ERP, the AF duration was 
decreased by AP14145. Again, the effect of AP14145 
on AF duration was dose dependent. Neither vernaka-
lant nor AP14145 changed the LV ERP significantly.
Effects of Compounds in 1-Week AT Pigs
The effects of vernakalant and AP14145 were compa-
rable in both 1-week AT and CTRL groups; both com-
pounds increased LA ERP and decreased AF durations 
with no significant changes of LV ERP (Table 2; Figure 6, 
bottom). The effects of AP14145 on LA ERP and AF 
duration were dose dependent.
In 5 of 6 pigs assigned to receive vernakalant and in 5 
of 6 pigs assigned to receive AP14145, the AF that was 
induced during baseline recording lasted for >30 min-
utes, and the infusion of the compounds was initiated 
while AF was still ongoing. Both vernakalant and the 
lowest dose of AP14145 terminated the AF in 5 of 6 pigs 
in each 1-week AT group. The time to conversion was 
13.8±5.5 minutes in the vernakalant group and 3.6±1.8 
minutes in the AP14145 group.
Cardioversion in Conscious Pigs
The average time for the development of sustained 
AF was 15.6±1.7 days of AT (Figure 7). On confirming 
sustained AF, the pigs received an infusion of 4 mg/kg 
vernakalant for 10 minutes and were observed for 30 
minutes. In 2 of 8 pigs, AF was converted to SR, where-
Figure 4. Expression of KCNN2 (left) and KCNN3 (right) in tissue from the 4 heart chambers isolated from healthy 
control (HC) pigs (n=6) and pigs with sustained atrial fibrillation (AF; n=6).  
LA indicates left atrial; and LV, left ventricle; RA, right atrial; and RV, right ventricle.
Figure 5.  Plasma concentrations of AP14145 in pig.  
Left, Measured total plasma concentration of AP14145 in pigs after bolus injection of 5 mg/kg AP14145 fitted with an expo-
nential 1-phase decay model. Right, Calculated free plasma concentration of AP14145 based on a plasma protein binding of 
88% after 3 injections of 5, 8, and 8 mg/kg of AP14145 with 30-min intervals.
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as AF remained unchanged in 6 of 8 pigs. The 2 pigs 
with conversion were tachypaced for an additional 1 
and 2 weeks, respectively, before they became resistant 
to vernakalant. On average, vernakalant-resistant AF 
was obtained after pacing for 18.8±3.3 days. One to 
2 days after having observed vernakalant-resistant AF, 
8 of 8 pigs still had sustained AF when the pacemaker 
was turned off. Vernakalant-resistant, sustained AF was 
cardioverted to normal SR by 5 mg/kg of AP14145 in 
4 of the 8 pigs, by an additional 8 mg/kg in 3 of the 
remaining 4 pigs, and with yet an additional dose of 
8 mg/kg AP14145 in the last pig (Figure 8, left). Sus-
tained AF (>10 minutes) could not be reinduced by 
burst pacing in any of the pigs 2 to 20 minutes after 
SR was restored. The time to conversion decreased 
with increasing doses of AP14145, from 16.3±7.9 min-
utes after 5 mg/kg AP14145 to 7.3±2.7 minutes after 
8+5 mg/kg AP14145 to 5.0 minutes after 5+8+8 mg/kg 
AP14145 (Figure 8, right).
DISCUSSION
We present the first results from a model of vernakalant-
resistant AF in conscious pigs showing that SK channel 
inhibition by AP14145 is capable of both converting 
vernakalant-resistant AF to SR and protect against rein-
duction of AF. Complementary molecular, biophysical, 
and molecular methods were used and showed that (1) 
SK2 and SK3 channels are present in the porcine atria 
in both HC and in pigs with vernakalant-resistant AF, 
(2) AP14145 is a reasonably potent and selective inhibi-
tor of the SK3 current, and (3) SK channel inhibition by 
Figure 6. Effects of vernakalant and AP14145 on left atrial (LA) effective refractory period (ERP), atrial fibrillation 
(AF) duration, and left ventricle (LV) ERP.  
Top, Effects in control pigs. Bottom, Effects in 1-wk atrial tachypacing pigs.
Table 1. Effects of Vernakalant and AP14145 in CTRL Pigs
 LA ERP, ms LA ERP (% of Baseline) AF Duration, s LV ERP, ms LV ERP (% of Baseline)
Vernakalant baseline 81±14 100±0 31 (26–39) 203±13 100±0
Vernakalant 130±20 169±27 8 (5–12) 193±9 95±3
AP14145 baseline 59±9 100±0 690 (382–1246) 163±9 100±0
5 mg/kg AP14145 110±14 191±13 9 (5–16) 177±13 108±6
5+8 mg/kg AP14145 140±13 249±24 3 (2–4) 173±17 106±7
5+8+8 mg/kg AP14145 159±15 281±23 2 (1–3) 173±17 106±7
AF indicates atrial fibrillation; CTRL, controls; ERP, effective refractory period; LA, left atrial; and LV, left ventricle.
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AP14145 selectively prolongs the refractory period in 
porcine LA but not in the LV.
SK channels are predominantly expressed in the atria 
compared with the ventricles in the normal heart of 
several species, including humans, with no differences 
between LA and RA.11,24–26 Functionally, SK channels 
play a greater role in the atria compared with the ven-
tricles when using effect criteria, such as ERP prolonga-
tion, action potential durations, and QT intervals.8,11,16 
These findings have led to the notion that SK channels 
might be an interesting target for development of novel 
treatment for AF where more atrial selective pharmaco-
therapy has long been sought for. Significant increases 
of both LA ERP and RA ERP without similar effects in the 
LV ERP or ventricular repolarization are promising results 
relating to both the efficacy and safety of the treatment.
Expression of Porcine Cardiac SK 
Channels
We present, for the first time, evidence that SK2 and 
SK3 but not SK1 subunits are expressed in porcine atria 
and ventricles in HC pigs and in pigs with vernakalant-
resistant AF. Skibsbye et al16 found that the SK1 subunit 
was minimally expressed in RA appendage tissue from 
patients in SR, as well as patients with >6 months in AF, 
but both the SK2 and SK3 channel subunits were pres-
ent in SR tissue as well as chronic AF tissue, although 
to a significantly lower extent in the latter. Considering 
the SK channel subtypes present in the atria, the pig 
seems to be more similar to man than, for example, 
the dog, where all 3 SK channel subtypes are present 
in the atria.11 According to the quantitative polymerase 
chain reaction data from the current study, SK channel 
mRNA was expressed in slightly higher amounts in both 
atria compared with the ventricles of both the control 
pigs and pigs with long-term AT. Although a tendency 
toward an increased SK3 expression in pigs with long-
term AT compared with HC pigs was observed in tissue 
from LA, RA, and to a lesser extent LV, this apparent 
upregulation of SK3 was not statistically significant.
Effects of AP14145 in Pigs
AP14145 is a new SK channel inhibitor that demon-
strated a reasonable selectivity toward cardiac SK 
channels compared with the other cardiac ion chan-
nels tested. The functional data from our open chest 
experiments suggest an atrial selective effect of 
AP14145. The LA ERP was concentration-dependently 
increased almost 3-fold by AP14145 while the LV ERP 
remained unchanged in both control pigs and pigs 
that underwent 1 week of AT. One explanation for 
this atrial selectivity of AP14145 could be differences 
in expression levels. As described above, SK channel 
mRNA was expressed in slightly higher amounts in the 
LA compared with the LV of both CTRL pigs and pigs 
with vernakalant-resistant AF. Other potentially con-
tributing explanations for this apparent atrial selective 
effect include Ca2+ dynamics in ventricles versus atria, 
location of the channels and neighboring L-type Ca2+ 
channels, transportation to the membrane, and redun-
dancy of other repolarizing currents in the ventricles 
that renders SK current relatively less important in the 
ventricles. These possibilities were not investigated in 
the present study.
Figure 7. Time to sustained atrial fibrillation (AF) in 
conscious pig.  
Sustained AF was defined as AF that was sustained after 
the pacemaker was turned off during >10 min monitor-
ing and an additional 10 min with infusion of saline (1 mL/
kg) followed by 30 min monitoring, a total of 50 min of AF. 
Vernakalant-resistant AF was defined as sustained AF where 
vernakalant (4 mg/kg) infused for 10 min did not cardiovert 
AF to sinus rhythm during a monitoring phase of an ad-
ditional 30 min.
Table 2. Effects of Vernakalant and AP14145 in 1-Week AT Pigs
 LA ERP, ms LA ERP (% of Baseline) AF Duration, s LV ERP, ms LV ERP (% of Baseline)
Vernakalant baseline 87±10 100±0 1057 (620–1801) 187±4 100±0
Vernakalant 155±18 184±15 21 (10–46) 195±6 105±3
AP14145 baseline 65±10 100±0 1208 (810–1801) 174±12 100±0
5 mg/kg AP14145 117±8 202±35 44 (20–100) 192±8 112±5
5+8 mg/kg AP14145 160±9 278±48 5 (3–7) 192±12 111±5
5+8+8 mg/kg AP14145 172±9 297±46 1 (1–2) 192±10 111±4
AF indicates atrial fibrillation; AT, atrial tachypacing; ERP, effective refractory period; LA, left atrial; and LV, left ventricle.
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The calculated peak free plasma concentration of 
AP14145 was ≈1, ≈2, and ≈2.5 µmol/L after each injec-
tion, whereas the infusion regimen of vernakalant that 
was used should produce a steady state free unbound 
concentration of 4.8 µmol/L based on a total plasma 
concentration of 4000 ng/mL,21 a molar weight of 349.5 
g/mol, and assuming a plasma protein binding of 58% 
based on the human plasma protein binding of 53% to 
63%.27 As expected, vernakalant increased the LA ERP 
and reduced AF duration in the open chest experiments 
in both CTRL and 1-week AT pigs. In these settings of 
no or little remodeling, the efficacy of vernakalant (4.8 
µmol/L free) and the lowest dose of AP14145 (1 µmol/L 
free) on AF duration and LA ERP were comparable. The 
highest dose of AP14145 had more prominent effects 
on LA ERP and AF duration even though the maximal 
free plasma concentration of AP14145 was only half of 
that of vernakalant.
In the long-term AT conscious pigs, vernakalant 
was administered as an infusion of 4 mg/kg given 
over 10 minutes. In the clinical phase I study of ver-
nakalant, this dose resulted in a Cmax of 2.0 to 2.2 
µg/mL which corresponds to a free unbound Cmax of 
≈3.5 µmol/L which is slightly more than the maximal 
plasma concentration of AP14145 that was used. 
The results of vernakalant and AP14145 in the long-
term AT pigs were different. AP14145 converted the 
vernakalant-resistant AF to SR in all 8 pigs tested. 
We cannot make firm conclusions on the mechanism 
behind the vernakalant-resistance, but it is likely not 
because of reduced expression of its main ion chan-
nel targets as we found that the expressions of KV1.5 
and NaV1.5 were not affected by AT (data not shown). 
This in concordance with other studies suggesting 
that the loss of cardioversion efficacy of vernakalant 
is likely not due at decreased effect of vernakalant on 
its target ionic currents but rather because of other 
AF stabilizing processes.28,29
AT and Cardiac Remodeling
The atrial selective effect observed in this study might 
be changed by certain pathophysiological conditions, 
such as myocardial infarction and congestive heart fail-
ure. Under these conditions, some studies have shown 
that ventricular SK current can be upregulated and that 
blocking SK current can exhibit both proarrhythmic30,31 
and antiarrhythmic32,33 ventricular effects, depending 
on the experimental setup.
The main focus of this study has been to examine 
whether SK channel inhibition could be beneficial in a 
setting of relatively early persistent AF with remodeling 
to a degree that renders pharmacotherapy for recent 
onset AF ineffective. Even though all the pigs undergo-
ing AT received digoxin to prevent symptoms of heart 
failure, there might be a component of ventricular 
remodeling in our pig model of AF because the ven-
tricular rate was increased during tachypacing. How-
ever, no symptoms of heart failure were observed. Also 
no signs of ventricular proarrhythmia in the presence 
of AP14145 were observed in any of the tested pigs. 
Whether SK channel inhibition can have any ventricu-
lar effects in pigs under pathophysiological conditions, 
such as myocardial infarction and congestive heart fail-
ure, thus remains an open question.
In patients with permanent (>6 months) AF, the 
atrial effective refractory period (AERP) is shortened, 
but in RA tissue from patients with paroxysmal AF, this 
does not seem to be the case.34–37 A recent study has 
revealed a correlation of the degree of left ventricu-
lar dysfunction to prolongation of atrial refractoriness, 
showing that decreased left ventricular function is 
associated with relative action potential duration pro-
longation in patients with SR, paroxysmal AF, as well as 
permanent AF.37
In our short-term AT group, 1 week of pacing 
increased the susceptibility to AF but changed the 
refractory periods in neither atria nor ventricles com-
pared with CTRL.
The absent change in AERP after short-term AT is dif-
ferent from what has been observed in dogs, goats, and 
sheep, where short-term tachypacing has been shown 
to significantly decrease atrial refractoriness.3,11,38 This 
discrepancy could be caused by species differences or 
ventricular remodeling resulting in decreased left ven-
tricular function. In the animal models demonstrating 
Figure 8. Cardioversion and 
protection against reinduction of 
vernakalant-resistant atrial fibril-
lation (AF) with AP14145.  
Left, Increasing doses of AP14145 
cardioverts vernakalant-resistant AF 
and protects against reinduction of 
AF in 8 of 8 vernakalant-resistant AF 
pigs. Right, Time to cardioversion of 
AF by increasing doses of AP14145 in 
vernakalant-resistant AF pigs.
 by guest on D
ecem
ber 4, 2017
http://circep.ahajournals.org/
D
ow
nloaded from
 
Diness et al; SK Channels and Atrial Fibrillation
Circ Arrhythm Electrophysiol. 2017;10:e005125. DOI: 10.1161/CIRCEP.117.005125 October 2017 11
abbreviated AERP, no signs of decreased left ventricular 
function were reported. In the dog and sheep models 
of AF, the atrioventricular node had been ablated, and 
in goats, AF does not seem to cause ventricular dys-
function.39 In a dog model of AF, in the presence of 
congestive heart failure caused by ventricular tachypac-
ing, the decrease in AERP was smaller (24%) than in a 
model of AF with no congestive heart failure (42%).40 
Likewise, in a pig model of AF with congestive heart 
failure induced by AT, no reduction of AERP was report-
ed after 7 days of pacing—on the contrary, a significant 
AERP prolongation was observed.41 We cannot exclude 
a component of ventricular dysfunction in our model. 
Even though the pigs received digoxin to prevent symp-
toms of heart failure, the ventricular rate was signifi-
cantly increased by AT, and the unchanged AERP value 
could therefore be speculated to result from the com-
bination of tachypaced induced shorting of AERP and 
concomitant prolongation associated with ventricular 
dysfunction.
AP14145 and Adverse Events
In the present study, we did not see any significant 
effects of AP14145 on the heart rate, the blood pres-
sure, the ventricular repolarization (LV ERP), or the 
QRS interval. In all the conscious long-term AT pigs, 
adverse effects, such as vomiting, were seen 20 to 30 
minutes after injection of AP14145. A dose of zoletil 
(a mixture of tiletamine hydrochloride and zolazepam 
hydrochloride) was used to remedy these effects 
but in effect left the pigs unconscious. Two of the 8 
vernakalant-resistant pigs cardioverted on AP14145 
before zoletil was injected, but in 6 of 8 pigs zoletil 
had been injected 2 to 40 minutes before cardiover-
sion was obtained. We cannot exclude that AP14145 
had been better tolerated if it had been given as an 
infusion over longer time.
Limitations
After the higher doses of AP14145, cardioversion was 
obtained within 10 minutes in all pigs, but we cannot 
rule out a possible cardiac impact of zoletil in 6 of the 8 
pigs. We cannot exclude that other effects of AP14145 
than SK channel inhibition could have influenced our 
findings. However, AP14145 did not affect a panel 
of relevant cardiac ion channels (Figure 3) and had a 
65- and 8-fold higher IC50 on hERG and IKACh as com-
pared with SK3. Moreover, based on the measured free 
plasma concentrations of AP14145 in our experiments, 
we do not anticipate a significant contribution from 
inhibition of hERG or IKACh. The small sample sizes for 
the quantitative polymerase chain reaction experiments 
and for the open chest CTRL pigs increase the chance 
of a type II error.
Summary and Conclusions
In healthy pigs and pigs that had been subjected to 
1-week AT, both vernakalant and AP14145 prolonged 
the AERP and reduced the duration of acutely induced 
AF while not significantly prolonging the LV ERP or show-
ing other signs of ventricular effects. In an advanced pig 
model of long-term AT-induced sustained AF where clin-
ically relevant doses of vernakalant could no longer con-
vert the AF to SR, AP14145 was able to convert the pigs 
to SR and protect against reinduction of AF. Vomiting 
needing attention occurred after all doses of AP14145 
that produced conversion to SR in pigs. The capability of 
SK channel inhibition to prolong atrial but not ventricu-
lar refractoriness and to convert vernakalant-resistant 
AF, as well as protecting from reinduction of AF, was 
confirmed in pigs with the tool compound AP14145. SK 
channel inhibition is an interesting concept and a prom-
ising target for development of new treatment of AF.
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 Supplemental material 
In vitro electrophysiology 
 
Automated patch clamp experiments 
SK, hERG, NaV1.5 and CaV1.2 experiments were performed using a QPatch 16 HT system and single-hole Qplates (Biolin 
Scientific, Sophion, Denmark). The Qpatch generates giga sealing, whole-cell formation, compound application and 
recording of current automatically. 
 
SK assay 
Automated whole-cell patch-clamping was performed on HEK-293 cells stably expressing hKCa2.3, in symmetrical K
+
 
solutions, with an extracellular solution consisting of (in mM): KCl 150; CaCl2 0.1; MgCl2 3; HEPES 10; Glucose 10, 
pH=7.4 with KOH, and an intracellular solution consisting of (in mM): KCl 108;  KOH/EGTA 31.25/10; CaCl2 8.1; MgCl2 
1.2; HEPES 10; KOH 15, pH adjusted to pH=7.2 with HCl. The free calcium concentration was calculated to 400 nM. The 
cells were clamped at 0 mV and hKCa2.3 currents were continuously elicited every 5th second by a linear voltage ramp from 
–80 mV to +80 mV (200 ms in duration). The compound application protocol consisted of 9 recording periods lasting from 
50-200 s: 1) Baseline recordings in extracellular solution; 2) Application of the positive control methyl-bicuculline (100µM) 
(Sigma), which is characterized by full efficacy, fast on- and off-rate; 3-4) Wash-out; 5-9) Increasing concentrations of test 
compound to establish an IC50 value.  Data were sampled at 10 kHz, 4th order Bessel filter, cut-off frequency 3 kHz. 
Currents were compensated for run-down. Potency was quantified as the concentration needed to inhibit half of the SK 
channel activity recorded at -80 mV and reported as an IC50 value. All drug effects were normalized to the observed full 
inhibitory effect of methyl-bicuculine.   
hERG Assay 
Recordings were performed on CHO-K1 cells stably expressing hKV11.1 with an intracellular solution containing (mM):  
CaCl2 5.4; MgCl 1.75; KOH/EGTA 31.25/10; KCl 120; HEPES 10; Na2ATP 4, pH pH=7.2 with KOH, and an extracellular 
solution (mM): CaCl2 2; MgCl2 1; NaCl 145; KCl 4, HEPES 10; Glucose 10, pH=7.4 with KOH. The cells were kept in 
voltage clamp and held at -90 mV. Currents were elicited every 7th ‘s second by depolarizing the membrane potential to 
+20 mV for 2 s followed by a 2 s voltage step to -50 mV in order to record tail currents. The application protocol used was: 
baseline recordings in extracellular solution followed by application of increasing concentration of AP14145 (1, 3, 10, 30, 
100 µM). Finally 100µM Dofetilide was added as a positive control. Effect of AP14145 on tail current amplitude was 
recorded at baseline and following drug application, normalized to full block by dofetilide and used to establish the IC50. 
Data were sampled at 10 kHz, 8th order Bessel filter, cut-off frequency 3 kHz, and 80% Rs compensation. Only 
experiments with a whole cell seal of > 500 MΩ were used. 
 
 
NaV1.5 assay 
The effect of AP14145 was examined using HEK293 cells stably expressing rNaV1.5. NaV1.5 currents were recorded with 
an intracellular solution that contained (in mM) 135 CsF, 1/5 EGTA/CsOH, 10 HEPES, 10 NaCl, 4 Na-ATP, pH 7.3, 300 
mOsm and an extracellular solution containing (in mM): 2 CaCl2, 1 MgCl2, 10 HEPES, 4 KCl, 145 NaCl, 10 glucose, pH 
7.2, 310 mOsm (adjusted with sucrose). rNaV1.5 currents were elicited every 1000 milliseconds by a 50 ms depolarizing 
step to -20 mV from a holding potential of -120 mV (a total of 80 pulses). The application protocol used was baseline 
recordings in standard extracellular solution followed by application of AP14145 (15µM). The current amplitude at the 80
th
 
pulse was used for analysis. Data were sampled at 25 kHz, eighth-order Bessel filter, cutoff frequency 3 kHz.  Only 
experiments with a whole-cell seal of >500 M[ohm] were used. 
Calcium assay 
 
Effect of AP14145 on L-type calcium channels was investigated by automated patch clamping (Qpatch, Sophion) using a 
hCaV 1.2 stable cell line (Alpha1C, Beta2C and Alpha2delta) (SB Drug Discovery).The extracellular solution contained (in 
mM): 145 NaCl, 10 BaCl2, 4 KCl, 10 HEPES and 10 Glucose (pH 7.4). The intracellular solution contained (in mM) 27 
CsF, 112 CsCl, 2 NaCl, 8.2 EGTA, 10 HEPES and 4 MgATP; (pH 7.25). The stimulus regime consisted of an initial 50 ms 
pulse at -120 mV, followed by a 300 ms test pulse at 0mV, and then returned back to -120 mV for another 50 ms. Four 
cumulative concentrations of compound was applied to the cell (1, 3, 10, 30 (in µM)), followed by the positive control, 
Nifedipine (10µM). 
 
 
 Two-electrode voltage-clamp 
cRNA for injection was prepared according to from linearized plasmids using the mMESSAGE mMACHINE T7 kit 
(Ambion, TX, USA). RNA concentrations and quality were assessed by UV spectroscopy (NanoDrop, Thermo Scientific, 
Wilmington, USA) and gel electrophoresis. The following concentrations of cRNA were used (µg/µL): KV7.1+KCNE1 0.08 
+ 0.02; Kir2.1 0.4; KV1.5 0,1; KV4.3+ KChIP2 0.01+0.01; Kir3.1+Kir3.4 0.04+0.04. 50 nL cRNA was injected in Xenopus 
laevis oocytes (EcoCyte Bioscience, Castrop-Rauxel, Germany),  and currents were recorded after 2-3 days of incubation 
(19
o
C) using a two-electrode voltage-clamp amplifier (Dagan CA-1B; IL, USA). Borosilicate glass recording electrodes 
(0.5–1 MΩ when filled with 2 M KCl) (Module Ohm, Herlev, Denmark) were pulled on a DMZ-Universal Puller (Zeitz 
Instruments, Martinsried, Germany). Oocytes were superfused with Kulori solution (in mM: NaCl 90, KCl 4, MgCl2 1, 
CaCl2 1, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 5, pH=7.4 with NaOH, room temperature). After stabilization 
the solution was changed for a solution containing AP14145 (30µM). For Kir3.1/kir3.4 four concentrations of AP14145 
were tested (1, 3, 10, 30 µM) in order to establish an IC50 value.  
Oocytes were voltage clamped at -80 mV. KV7.1/KCNE1 currents were elicited by depolarizing the membrane potential to 
+20 mV for 5 s followed by a 1 s step to -30 mV. KV1.5 and KV4.3/KChIP2 currents were evoked by changing the 
membrane potential to +20 mV or 0 mV for 2 s respectively. Steady state current amplitudes (KV7.1/KCNE1 and KV1.5) 
and peak current amplitudes (KV4.3/KChIP2) were used for analysis. Kir3.1/Kir3.4 and Kir2.1 currents were elicited by a 
ramp protocol from -100 mV to +80 mV (5 s duration). Current amplitudes at -100 mV were used for analysis. 
Data acquisition was performed with the Pulse software (HEKA Elektronik, Lambrecht/Pfalz, Germany). 
 
KCNNx expression in pig hearts 
 
Tissue samples 
After premedication with zoletil pig mixture (250 mg dry tiletamin+zolazepam, 6.5 ml xylazine 20 mg/ml, 1.25 ketamine 
100 mg/ml, 2.5 ml butorphanol 10 mg/ml, and 2 ml methadone 10 mg/ml) 1 ml/10 kg given IM, the pigs were euthanized 
by intravenous injection of pentobarbital 200 mg/ml. The hearts were immediately excised and placed in ice-cold 
cardioplegic solution (NaCl 110.0 mM, KCl 16.0 mM, MgCl2 16.0 mM, CaCl2 1.2 mM,  NaHCO3 10.0 mM). Cardiac 
tissue from each of the four chambers was obtained from long-term AT pigs (n=6) or controls (n=6) and rapidly snap-frozen 
in liquid nitrogen. Tissue was kept at -80°C for later RNA extraction. 
Approximately 40mg of atrial and ventricular tissue specimens were lysed in QIAzol reagent (QIAGEN, Maryland, USA) 
using a Precellys 24 (Bertin Technologies, Montigny-le-Bretonneux, France). Total RNA including small RNAs was 
purified according to the manufacturer’s instruction using the miRNeasy Mini kit (QIAGEN, Hilden, Germany). RNA 
samples were treated with DNAse. The RNA concentration and purity was determined by spectrophotometry 
(NanoDrop2000, Thermo Scientific, Wilmington, USA) using the absorbance ratio of A260/A280.  
Expression profiling 
Reverse transcription (RT) reactions were performed following the manufacturer’s instructions using the Precision 
nanoScript2 Reverse Transcription kit (PrimerDesign Ltd., Southampton, UK). Each reaction had a final volume of 20 µL 
containing 1µg of total RNA. The experiment included a minus reverse transcriptase control (-RT) to check for genomic 
contamination and other amplification artifacts. The reverse transcription steps were conducted in a PTC-200 Peltier 
Thermal Cycler (Struers KEBO Lab, Albertslund, DK) as follows: 25°C for 5 minutes, 42°C for 20 minutes and 75°C for 10 
minutes. To assess the levels of mRNAs from the genes KCNN1, KCNN2 and KCNN3 in the samples, quantitative real-
time polymerase chain reaction (qPCR) was carried out in duplicates using Custom real-time PCR assays with double dye 
probe (Taqman style) and PrecisionPLUS MasterMix with ROX (PrimerDesign Ltd., Southampton, UK) according to 
manufacturer’s instruction. GAPDH and GPI were used as reference genes for qPCR normalization and no template 
controls (NTCs) were run simultaneously to assess contamination. The qPCR steps were conducted with Precision 
BrightWhite real-time PCR 96-well plates (PrimerDesign Ltd., Southampton, UK) on a CFX Connect Real-Time System 
(BIO-RAD, Hertfordshire, UK) as follows: 95°C for 2min followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 
minute with FAM dye fluorescence read at the end of each cycle. Threshold cycle (Ct) values were obtained using Bio-Rad 
CFX96 Managed 3.0 software and assuming a single threshold mode. The data was transferred to a spreadsheet for 
calculation of ΔCts and the relative expression of the genes in both groups was calculated using the 2-ΔCt method.  
  
Primer sequences 
 
 
